Is the Serina Therapeutics (SER) investment thesis intact?

It is under pressure. Readouts currently rates the Serina Therapeutics Thesis Challenged. Serina's long-acting apomorphine SER-252 moves up in dose; topline due early 2027.

What is the next catalyst for Serina Therapeutics (SER)?

The next dated event is Phase 1b topline results (SER-252-1b) for SER-252, expected 1H 2027, as stated by the company.

How long will Serina Therapeutics' cash last?

Serina Therapeutics has said its cash will fund operations into H2 2027 (guidance as of March 23, 2026).

SERSerina Therapeutics, Inc.

Market reactionShares fell 16% on Nov 6.

ChallengedLast material event Sep 9, 2026 · Updated Oct 25, 2026

Serina's long-acting apomorphine SER-252 moves up in dose; topline due early 2027

Serina Therapeutics is a clinical-stage company using its POZ polymer platform to make long-acting versions of known drugs, led by SER-252 for advanced Parkinson's disease; none is approved.

Serina's case rests on SER-252, apomorphine attached to its POZ polymer to give steady drug levels from a subcutaneous injection in advanced Parkinson's disease. Serina plans an FDA 505(b)(2) filing that relies on apomorphine's known profile. In the first group of eight patients, drug levels stayed elevated and some patients' motor function improved on exploratory measures. The safety committee cleared a higher dose. Topline single-dose data are due in the first half of 2027. Cash was $23.0 million, with going-concern doubt.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

Single-dose data show steady drug levels and motor benefitAwaiting evidenceSingle-ascending-dose topline data (first half of 2027).Next: Single-ascending-dose topline data (first half of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Dose escalation stays on trackSupportedCohort 2 safety review, ahead of topline data in the first half of 2027.Next: Cohort 2 safety review, ahead of topline data in the first half of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Serina funds the trial to its 2027 dataAt riskQ3 2026 cash balance.Next: Q3 2026 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

SER-252 single-dose topline data

Tests: Single-dose data show steady drug levels and motor benefit

First half of 2027

Do higher single doses give sustained apomorphine levels, acceptable safety and signs of motor benefit?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical

+2.8%Sep 9, 2026

Serina's long-acting apomorphine SER-252 moves up in dose; topline due early 2027

ChallengedRegulatory

+30.1%Jan 28, 2026

FDA IND Clearance for SER-252

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Parkinson's disease

SER-252 · 1 upcoming · 3 completed

Phase 1b Data: ToplineSER-252-1b

1H 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Serina Therapeutics (SER) investment thesis intact?: It is under pressure. Readouts currently rates the Serina Therapeutics Thesis Challenged. Serina's long-acting apomorphine SER-252 moves up in dose; topline due early 2027.
What is the next catalyst for Serina Therapeutics (SER)?: The next dated event is Phase 1b topline results (SER-252-1b) for SER-252, expected 1H 2027, as stated by the company.
How long will Serina Therapeutics' cash last?: Serina Therapeutics has said its cash will fund operations into H2 2027 (guidance as of March 23, 2026).

Other companies we cover in these diseases

Parkinson's disease: Biohaven (BHVN)Gain Therapeutics (GANX)MeiraGTx (MGTX)ProMIS Neurosciences (PMN)

Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.